[ Ray/Carol, chat and PGEN ]
>>PS: Watch what you say to Rick. He's gonna be hard to talk to after he counts all that
Cash.<<
Nah. Unfortunately, even when I'm as certain as I have been about MOGN, I stay ultra-diversified. I haven't got much riding on it or on CVAS. That's one thing that I want to learn to do.... let a bigger chunk of resources rest on "timed/charted" stuff. That's what I'm doing here on your thread.... learning. This run with MOGN has been different for me, however..... I usually sell into strength, but, this time, I've been buying more as we go.
PGEN..... Cambridge Antibody is a Class Act. Think of them as the PDLI of Europe. My comment to some friends yesterday when I saw the news..... "Nothing earth-shaking about this,
but it is a collaboration with a very good company."
It's a bit more positive than you realize, yes. On the other hand, you're correct..... CAT is getting the better deal. PGEN has little choice, however.... they can sit and, wishing that they could cover the additional bases (antibodies and the lessons to be learned from a convenient source of agonists or antagonists), get shut out, or they can collaborate. This is a fishing expedition, but they're going out with the best of guides.
There are two ways to build a biotech. I like the first.... find a great technology and fund/foster it. The second? Find a mediocre idea, put spit shine on it, and let the public get a whiff. When you've got some money, go fishing.
They came very, very close to big-time success with IPIC. The toxicity problems encountered with dex were not those that were of concern prior to approval, and the remainder of the business plan had fallen into place.
Movers/shakers.
Cheers! Rick |
